A real-world, open-label, multi-center, prospective, non-interventional (observational) study to evaluate the effectiveness and tolerability of ceritinib in Indian patients with ALK positive metastatic non-small cell lung cancer who have progressed or are intolerant to crizotinib. - CONNECT-CLDK378AIN01
Latest Information Update: 12 Nov 2019
At a glance
- Drugs Ceritinib (Primary) ; Crizotinib
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Novartis
- 16 Nov 2016 New trial record